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ABSTRACT
Previous studies have demonstrated that delivery of a recombinant adeno-associated virus (AAV) vector en-
coding the complete human cystic fibrosis transmembrane regulator (CFTR) cDNA (tgAAVCF) to the nose,
sinus, and lungs of subjects with cystic fibrosis (CF) was safe and well tolerated. In a small randomized, dou-
ble-blind study of three doses of aerosolized tgAAVCF or placebo at 30-day intervals, encouraging but non-
significant trends in pulmonary function and induced sputum interleukin 8 (IL-8) levels were seen at early
time points. This larger study was conducted to verify these trends. One hundred and two subjects aged 12
years and older with mild-to-moderate cystic fibrosis (forced expiratory flow in 1 sec [FEV1] : 60% predicted)
were randomized to two aerosolized doses of 1  1013 DNase-resistant particles of tgAAVCF (n  51) or match-
ing placebo (n  51) administered 30 days apart. Although tgAAVCF was well tolerated, the study did not
meet its primary efficacy end point of statistically significant improvement in FEV1 30 days after initial ad-
ministration of tgAAVCF compared with placebo. There were no significant differences in spirometric lung
function over time, induced sputum biologic markers, or days of antibiotic use in either treatment group. Thus
repeated doses of aerosolized tgAAVCF were safe and well tolerated, but did not result in significant im-
provement in lung function over time. Because gene transfer is the simplest, most basic way to correct the
underlying genetic defect that leads to disease in CF, further research is warranted to develop an effective
gene transfer agent for the treatment of CF.
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OVERVIEW SUMMARY
In this study, 102 subjects aged 12 years or older with mild-
to-moderate cystic fibrosis (FEV1 : 60%) received two doses
of tgAAVCF or matching placebo administered 30 days
apart via nebulizer. The study drug was safe and well tol-
erated. The pattern of adverse events was similar between
subjects who received tgAAVCF and those who received
placebo. In contrast to the smaller, phase 2 study that pre-
ceded this study, no difference in the change in FEV1 or 
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IL-8 levels was noted between treatment groups. The num-
ber of days of antibiotic use was comparable between treat-
ment groups. This study, the largest gene transfer study con-
ducted in CF patients to date, demonstrates the safety of
adeno-associated virus vectors administered by aerosol de-
livery but also suggests the need for further improvement
in gene transfer technology and/or more appropriate clini-
cally relevant efficacy end points.
INTRODUCTION
CYSTIC FIBROSIS (CF) is an autosomal recessive disease withan incidence of approximately 1 in 4000 live births in large
U.S. newborn screened populations (Therrell et al., 2005). CF
is characterized by progressive lung disease due to chronic bac-
terial colonization, malabsorption due to exocrine pancreatic in-
sufficiency, abnormal regulation of salt transport across the gas-
trointestinal and respiratory epithelium, and male infertility due
to absence or stenosis of the vas deferens (Koch and Hoiby,
1993; Rosenfeld et al., 1993). In the United States, the pre-
dicted median survival of an individual with CF is 36.5 years
(Cystic Fibrosis Foundation, 2006). More than 90% of mortal-
ity in CF is due to respiratory failure from progressive lung dis-
ease.
The cystic fibrosis transmembrane regulator (CFTR) gene,
located on chromosome 7, encodes a 1480-amino acid residue
protein that functions, at least in part, as a cAMP-regulatable
chloride channel on the apical surface of the epithelium. The
most common mutation of the CFTR gene is F508, a dele-
tion of the codon for the phenylalanine at location 508 (Koch
and Hoiby, 1993; Rosenfeld et al., 1993). When normal copies
of the CFTR gene are transferred to human respiratory ep-
ithelial cells in cell culture, CFTR DNA and mRNA are ex-
pressed with accompanying restoration of normal ion trans-
port, suggesting potential correction of the defect and of the
phenotype.
Delivery of the normal gene to the lungs of subjects with CF
has presented several challenges, including the identification of
an acceptable vector. Adeno-associated virus (AAV) is a capa-
ble vector for this purpose. AAV is not known to cause disease,
nor is it a transforming or oncogenic virus. AAV exists mainly
as an unintegrated episomal concatemer in vivo (Schnepp,
2005), and no significant alterations in cell growth or mor-
phology have been documented when AAV is integrated into
human cell lines in vitro. AAV is a replication-defective vec-
tor, capable of high-frequency stable gene transfer and expres-
sion in a variety of cells, including respiratory epithelial cells
from subjects with cystic fibrosis (Carter, 1992; Egan et al.,
1992; Flotte et al., 1992, 1993). tgAAVCF is a recombinant
vector encoding the complete human CFTR cDNA developed
for clinical use. When tgAAVCF was administered to rabbits
and monkeys, physiologically active, nonmutated, human
CFTR DNA and mRNA were recovered from lung cells (Con-
rad et al., 1996). Human respiratory epithelial cells that have
been transfected with tgAAVCF in vitro also express human
CFTR DNA and mRNA (Flotte et al., 1993).
Clinical trials of tgAAVCF have been conducted. Phase 1
studies focused on safety, evaluating tgAAVCF-mediated gene
transfer to the maxillary sinus cavity by direct instillation, to
the right lower lobe delivered by bronchoscopic lavage, and to
the whole lung by aerosol administration. The vector was well
tolerated in these studies and dose-dependent gene transfer was
observed (Wagner et al., 1998, 1999, 2002; Aitken et al., 2001;
Flotte et al., 2003).
A phase 2 multicenter double-blind placebo-controlled study
was conducted to evaluate the safety of multiple doses of
aerosolized tgAAVCF in CF subjects. tgAAVCF was well tol-
erated and safe. Gene transfer was noted in a subset of subjects
undergoing bronchoscopy, with a median copy number of
29–100 genomes per cell, depending on the site of brushing.
Nonsignificant trends to improved pulmonary function and re-
duced sputum interleukin (IL)-8 levels were observed at early
time points (Moss et al., 2004). A follow-up phase 2B study
was designed to extend these observations and further investi-
gate the safety, potential durability, and benefit of aerosolized
multidose delivery of tgAAVCF.
MATERIALS AND METHODS
Study agent
The active study agent was tgAAVCF, a recombinant AAV2
vector genetically engineered to contain the complete coding
region of the human CFTR cDNA. The vector was constructed
by replacing the entire wild-type AAV viral coding sequence
with the full-length human CFTR cDNA and a synthetic
polyadenylation sequence based on murine -globin. This con-
struct was flanked by the AAV inverted terminal repeat se-
quences that are required for viral replication and packaging
during the manufacturing process. tgAAVCF was formulated
in a sterile isotonic buffered salt solution containing calcium
and magnesium. Placebo consisted of the sterile isotonic
buffered salt solution containing calcium and magnesium.
tgAAVCF was produced under current Good Manufacturing
Practice guidelines at Targeted Genetics (Seattle, WA). The
tgAAVCF product used in the present study was produced by
the same process, and as part of the same manufacturing cam-
paign, as the tgAAVCF product that was used in the previous
smaller phase 2 trial (Moss et al., 2004).
Both tgAAVCF and matching placebo were administered
with the PARI LC Plus nebulizer (PARI, Midlothian, VA) us-
ing an AutoNeb controller that restricted the aerosol generation
to the inspiratory phase of the respiratory cycle of the subject.
The nebulizer was equipped with a one-way valve and an ex-
halation filter. It is estimated that about one-third of the nom-
inal tgAAVCF dose reaches the lower respiratory tract with this
system (Leung et al., 2007).
Study population
Subjects were recruited to this randomized, placebo-con-
trolled, double-blind study from 12 CF centers in the United
States. The study was approved by the institutional review
boards and institutional biosafety committees of the participat-
ing institutions, and informed consent was obtained from all
subjects. The protocol was reviewed and approved by the U.S.
Food and Drug Administration (FDA, Rockville, MD) and the
National Institutes of Health (Bethesda, MD) Recombinant
DNA Advisory Committee.
Entry criteria included a confirmed diagnosis of CF, defined
as clinical features of CF plus either a positive sweat chloride
60 mEq/liter or two identifiable mutations consistent with CF;
forced expiratory volume in 1 sec (FEV1) 60% predicted for
age; and age 12 years. Exclusion criteria included receipt of
intravenous antibiotics for a respiratory infection within 30 days
of screening, severe hemoptysis, lung transplantation, cigarette
smoking within 90 days of screening, and known substance
abuse within 30 days of screening.
Study design
In this randomized, double-blind, placebo-controlled study,
subjects (dosing goal, n  100) were randomized at a 1:1 ratio
to two aerosolized doses of either 1013 DNase-resistant particles
(DRP) of tgAAVCF or matching placebo (buffered salt solution)
administered 30 days apart with the PARI LC Plus nebulizer.
Sample size calculations were based on the effect sizes ob-
served for the 30-day change in FEV1 (liters) and 14-day change
in sputum IL-8 concentration (log10 ng/ml) in the initial phase
2 multidose aerosol study, in which subjects received three
doses of 1  1013 DRP of tgAAVCF or placebo at 30-day in-
tervals (Moss et al., 2004). Enrollment of 100 subjects, 50 in
each treatment arm, would provide 93% power to detect a 0.14-
liter difference in the 30-day change in FEV1 between treat-
ment groups, assuming a standard deviation of the change of
0.20 liter in each group. This sample size would also provide
adequate power for detecting 0.3 log10-ng/ml differences be-
tween treatment groups in IL-8. A planned interim futility anal-
ysis was also performed, which resulted in completion of the
trial.
Study procedures
After completion of screening procedures, eligible subjects
were randomized and received study drug by inhalation on
study days 0 and 30. Pulmonary function testing was performed
at screening, before dosing, and then every 14 to 15 days until
90 days after first study drug administration. Subjects under-
went sputum induction for determination of sputum biologic
markers (IL-8, DNA, neutrophil elastase, and protein concen-
trations) at screening, and then 14 and 45 days after first study
drug administration. Sputum biomarkers were determined at a
central laboratory as previously described (Moss et al., 2005).
Adverse events were collected at study visits for the first 90
days after first study drug administration, and then by telephone
interview at study days 150 and 210.
The primary end point was 30-day change in absolute FEV1.
Secondary end points were changes in absolute FEV1 values,
FEV1 % predicted, forced vital capacity (FVC), and mid-max-
imal expiratory flow rate (FEF25-75) over serial time points from
14 to 90 days after first dosing, changes in induced sputum bi-
ologic markers over time, number of days of antibiotic use, and
safety.
The study was overseen by a Data Safety Monitoring Com-
mittee (DSMC) of the Cystic Fibrosis Foundation. The DSMC
was an independent, multi-disciplinary group consisting of
physician subspecialists and a statistician who, collectively,
have experience in treating patients with cystic fibrosis and in
the conduct of randomized clinical trials. The DSMC convened
on four occasions to review available, unblinded safety data.
Each time the DSMC recommended study continuation.
RESULTS
A total of 122 subjects were screened for the study; 109 sub-
jects were randomized and 102 received treatment. Of the 102
subjects who received treatment, 98 completed the study and 4
discontinued early. Of the four early discontinuations, one was
in the tgAAVCF treatment group and three were in the placebo
group. The reason the subject who received tgAAVCF discon-
tinued early was loss to follow-up. Reasons for early discon-
tinuation among the placebo recipients included experiencing
an adverse event (unlikely to be related pulmonary exacerba-
tion), death (unrelated motorcycle accident), and other (no re-
sponse to day 210 phone call).
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TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICSa
tgAAVCF Placebo
(n  51) (n  51)
Age, years 23.9  10.9 21.3  8.7
Gender
Male 26 (51%) 28 (55%)
Female 25 (49%) 23 (45%)
CF genotype
AF508 homozygous 27 (53%) 27 (53%)
AF508 heterozygous 18 (35%) 20 (39%)
FEV1, % predicted 84.7  13.7 87.9  15.5
aData are presented as number (%) or mean  standard de-
viation.
Abbreviations: CF, cystic fibrosis; FEv1, forced expiratory
volume in 1 sec; tgAAVCF, vector endocing the complete hu-
man cystic fibrosis transmembrane regulator.
TABLE 2. ADVERSE EVENT OVERVIEW
tgAAVCF Placebo
(n  51) (n  51)
Number of Number (%) Number of Number (%)
events of subjects events of subjects
Treatment-emergent AEs 515 50 (98%) 521 51 (100%)
Serious adverse events 022 13 (26%) 015 11 (22%)0
Toxicity grade 3 030 13 (26%) 031 11 (22%)0
Abbreviation: AE, adverse event.
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The demographics and clinical characteristics of the subjects
dosed in the two treatment groups were similar (Table 1). In
general, subjects had mild lung disease (mean FEV1, 86.3%
predicted overall), and were relatively young, with 23 subjects
between 12 and 14 years of age, and 23 subjects between 15
and 17 years of age.
Safety results
A total of 1036 treatment-emergent adverse events were re-
ported among 101 of 102 subjects. The proportion of subjects
experiencing one or more adverse events, one or more serious
adverse events, or one or more toxicity grade 3 adverse events
was similar between the two treatment groups (Table 2).
A total of 37 serious adverse events were reported among 13
tgAAVCF subjects and 11 placebo subjects. None were con-
sidered definitely or probably related to study drug. Serious ad-
verse events that occurred among tgAAVCF subjects included
16 CF pulmonary exacerbations and 1 episode each of hemop-
tysis, asthma, pneumonia, colitis, fractured elbow, and intesti-
nal obstruction. Serious adverse events that occurred among
placebo recipients included 10 CF pulmonary exacerbations, 2
cases of hemoptysis, and single instances of fatal motorcycle
accident, nasal polyps, and dyspnea.
The proportion of subjects experiencing frequent adverse
events (occurring in 20% of subjects overall) was similar be-
tween treatment groups. Although fever was more common in
subjects receiving tgAAVCF than placebo, the difference was
not statistically significant. As expected among subjects with
CF, respiratory adverse events were common (Table 3).
Sera for neutralizing titers to AAV2 capsid were obtained at
baseline and on days 14, 45, and 75. At baseline, 68% of sub-
jects had anti-AAV2 neutralizing titers below the limit of de-
tection (1:4). Titers ranged from undetectable to 1:65,536,
with a geometric mean of 1:15. As expected, all subjects ex-
posed to tgAAVCF developed 4-fold or greater rises in anti-
AAV2 capsid-neutralizing titers (Table 4). Among subjects ex-
posed to tgAAVCF, geometric mean titers were 1:90, 1:1963,
and 1:1370 on days 14, 45, and 75, respectively. In contrast,
geometric mean titers for subjects who received placebo were
1:15, 1:15, and 1:14 on days 14, 45, and 75, respectively. No
adverse events associated with the development of AAV2 neu-
tralizing titers were noted.
Efficacy results
Spirometric pulmonary function tests were performed every
14 or 15 days from screening until 90 days after the first dose
of study medication. Pulmonary function was comparable be-
tween treatment groups at baseline. No improvement in FEV1
was noted 30 days after initial dosing, or at any time point,
when the tgAAVCF group was compared with the placebo
group (mean difference in day 30  baseline FEV1 between
tgAAVCF and placebo  0.03 liter, p  0.42; Fig. 1A). In con-
trast, there was improvement in FEV1 30 days after initial dos-
ing (p  0.04) in the preceding, smaller phase II study when
the tgAAVCF group was compared with the placebo group (Fig.
1B). No significant differences in other spirometric pulmonary
function parameters, including FEV1 % predicted, mean forced
expiratory flow during the middle half of the forced vital ca-
pacity (FEF25–75%), and forced vital capacity (FVC), were noted
between treatment groups over time (data not shown).
Adequate induced sputum samples at all time points were
available for 48 actively treated and 49 placebo-treated sub-
jects. IL-8 concentrations were measured in samples obtained
at baseline, and on days 14 and 45. There were no differences
in sputum IL-8 levels between treatment groups at any time
point (Fig. 2A). In contrast, there was a significant change in
TABLE 3. INCIDENCE OF MOST FREQUENT ADVERSE EVENTSa
tgAAVCF Placebo
(n  51) (n  51)
Cough increased 34 (67%) 38 (75%)
Rhinitis 30 (59%) 35 (69%)
Sputum increased 19 (37%) 23 (45%)
Pharyngitis 22 (43%) 19 (37%)
Sinusitis 12 (24%) 15 (29%)
Headache 12 (24%) 15 (29%)
Lung function decreased 14 (28%) 10 (20%)
Asthenia 11 (22%) 13 (26%)
CF pulmonary exacerbation 13 (26%) 10 (20%)
Abdominal pain 08 (16%) 14 (28%)
Fever 14 (28%) 07 (14%)
aData are presented as number (%) of subjects with AE. Most frequent adverse events
are defined as adverse events occurring in 20% of subjects overall.
TABLE 4. SERUM AAV2 NEUTRALIZING ANTIBODY TITERS
AND CHANGE OVER TIME BY TREATMENT GROUPa
tgAAVCF Placebo
(n  51) (n  51)
Positive baseline titer 17 (33%)0 16 (31%)
Fourfold or greater rise
Day 14 29 (59%)0 01 (2%)
Day 45 49 (100%) 03 (6%)
Day 75 50 (100%) 01 (2%)
aData are presented as number (% tested). Seronegative, a
titer value of 1:4; seropositive, a titer of 1:4 or greater.
induced sputum IL-8 levels on day 14 (p  0.03) in the previ-
ous phase II study (Fig. 2B). No differences in other induced
sputum biologic markers, including neutrophil elastase, DNA,
and protein, were found between treatment groups over time
(data not shown).
The use of intravenous antibiotics for the treatment of pul-
monary infection was recorded throughout the study. The pro-
portion of subjects who required intravenous antibiotics was
similar between active and placebo recipients, with 14% of sub-
jects who received tgAAVCF and 16% of subjects who received
placebo requiring at least one course of intravenous antibiotics
for pulmonary infection. The mean number of courses of anti-
biotics (0.16  0.42 vs. 0.18  0.43) and days of antibiotic
treatment (2.3  6.0 vs. 2.3  6.9) was comparable between
active and placebo recipients, respectively.
CONCLUSIONS
Cystic fibrosis has been considered a prime candidate for
gene complementation because it is a monogenic, autosomal re-
cessive defect; even small amounts of functional CFTR are suf-
ficient to protect the lung against disease, and only a small pro-
portion of the cells in an epithelium may need to express CFTR
in order to correct epithelial chloride transport. Several gene
transfer vectors, including AAV, have been used to deliver the
CFTR in preclinical models and CF patients. In this paper, we
show that repeated administration of aerosolized tgAAVCF to
the lungs is safe and well tolerated. The pattern and severity of
adverse events were similar between the two treatment groups.
CF genotype distributions were similar in active and placebo
arms. However, the encouraging trends in pulmonary function
and induced sputum IL-8 levels observed in an earlier, smaller
phase 2 study were not confirmed in the current study. No im-
provement in lung function was observed 30 days after initial
dosing when the tgAAVCF-treated group was compared with
the placebo group. Moreover, there were no changes in lung
function over time in either treatment group. No significant dif-
ferences were found in induced sputum biologic markers, in-
cluding IL-8, neutrophil elastase, DNA, or protein concentra-
tion, between treatment groups at any time point. Finally, the
use of intravenous antibiotics for pulmonary infections was sim-
ilar between treatment groups.
The failure of this trial to meet its primary end-point effi-
cacy measure raises two key questions about transfer of CFTR
to the respiratory epithelium via the tgAAVCF vector. First,
there is the question of adequacy of transgene expression by
this vector and route. Prior clinical studies have shown potent
tgAAVCF transgene transfer by direct polymerase chain reac-
tion (PCR) but low or undetectable transgene mRNA expres-
sion in respiratory epithelial cells as measured by reverse tran-
scriptase (RT)-PCR in cells obtained by bronchial brushing
(Aitken et al., 2001; Moss et al., 2004). However, because the
level of endogenous CFTR expression, clearly sufficient for bi-
ological function, is only about one copy per cell (Trapnell et
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FIG. 1. (A) Mean change in FEV1 over time in the current
(study ID number 25E01) phase 2 study. (B) Mean change in
FEV1 over time in the preceding (study ID number 25B01)
phase 2 study (Moss et al., 2004).
FIG. 2. (A) Mean change in induced sputum IL-8 levels over
time in the current (25E01) phase 2 study. (B) Mean change in
induced sputum IL-8 levels over time in the preceding (25B01)
phase 2 study (Moss et al., 2004).
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al., 1991), it is important to establish whether a similar level of
transgene expression can result in physiological correction. By
using more sensitive assays performed on primary nasal cells
harvested from tgAAVCF recipients participating in one of the
phase 1 trials (Flotte et al., 2003), it was shown that physio-
logical correction of cAMP-activated chloride channel function
was in fact achieved, and that the presence of tgAAVCF vec-
tor genomes correlated with CFTR mRNA expression and phys-
iological correction (Flotte et al., 2005). Thus, the lack of trans-
gene-specific CFTR mRNA in the prior phase 2 study does not
mean that gene correction was not attained (Moss et al., 2004),
but rather that technical means of verifying correction in the
lower respiratory tract remain insufficient to settle the question
and need further refinement. To reduce invasive perturbation
of the airways, bronchoscopy and bronchial brushings were not
performed in the study reported here.
The second key question provoked by our negative primary
efficacy end-point finding is that of appropriate selection of rel-
evant and meaningful outcome measures for gene therapy of
cystic fibrosis. The current study design and end point were
based on a preliminary suggestion of short-term improvement
in lung function following the first dose of tgAAVCF in the
prior phase 2 trial (Moss et al., 2004), which drove both sam-
ple size and choice of 30-day FEV1 as the primary outcome
measure. The previously observed improvement in FEV1 30
days after treatment was not seen in this trial (Fig. 1). Because
AAV2 is slow to express at the mRNA level, taking at least 30
days in airway epithelium, the primary time point may have
been too early; however, later improvements were not observed
either (Fig. 1A). In addition, inspection of 30-day FEV1 changes
in groups receiving placebo during numerous CF drug trials
conducted by the Cystic Fibrosis Therapeutics Development
Network reveals a wide variety in responses, from sharp drops
to increases in this measure (N. Mayer-Hamblett, personal com-
munication).
The treatment effect in placebo-controlled trials depends on
the impact of both the active drug and placebo on the subjects
in each group. Regarding the pulmonary effect of a gene ther-
apy intervention, a more likely treatment effect would be slow-
ing of disease progression (manifested in reduced loss of air-
flow over time or reduced rate of pulmonary exacerbations)
rather than an early boost in airflow similar to what has been
observed with inhaled mucolytic or antibiotic interventions
(Fuchs et al., 1994; Ramsey et al., 1999). It thus remains en-
tirely possible that the efficacy of tgAAVCF has been missed
because of selection of the wrong primary end point. Longer
term gene therapy trials using biomarkers and clinical end
points most likely to reflect CFTR correction seem advisable if
the field is to progress, a strategy adopted by the U.K. Cystic
Fibrosis Gene Therapy Consortium (Griesenbach et al., 2006).
In our study early improvement in sputum biomarkers (sec-
ondary efficacy measures in this trial included IL-8, DNA, and
elastase levels) did not occur, and may also require longer ob-
servation periods to be affected by a gene correction strategy.
Gene transfer remains the most basic way to correct the un-
derlying genetic defect that leads to disease in CF. Although
repeat administration of tgAAVCF did not result in early im-
provement in pulmonary function as measured by FEV1, treat-
ment with this AAV vector was safe and well tolerated. Ma-
nipulations of AAV vectors to enhance transduction, and
potentially efficacy, include adding an intron, changing vector
serotype, and coadministering proteasome inhibitors such as
doxorubicin, all of which are currently under investigation
(Carter, 2004; Zhang et al., 2004; Liu et al., 2006). Further stud-
ies on the potential effect of viral capsid-induced neutralizing
antibodies, well documented in our studies, and even potential
antibody responses to CFTR, are needed. Computational mod-
eling suggests the possibility of cellular immune responses
against putative CFTR T cell epitopes, including F508
(Figueredo et al., 2007). Other potential nonviral vector deliv-
ery systems for correction of the genetic defect in the cystic fi-
brosis airway include compacted DNA technology and plasmid
DNA–liposomes (Griesenbach et al., 2006). Finally, the role of
innate and adaptive immune responses to gene delivery to the
airway surface needs ongoing research to better define obsta-
cles and to develop methods of safely overcoming them.
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